Skip to main content

Table 1 Demographic, clinical, pathological, and surgical characteristics of the patients

From: Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy

Variables Total population [n (%), n = 1593] Development set [n (%), n = 1186] Validation set [n (%), n = 407]
Age [median (IQRa)] 67.0 (57.0, 77.0) 68.0 (57.0, 77.0) 66.0 (55.0, 77.0)
 ≤65 715 (44.9) 520 (43.8) 195 (47.9)
 66–80 644 (40.4) 492 (41.5) 152 (37.3)
 > 80 234 (14.7) 174 (14.7) 60 (14.7)
Sex
 Male 1032 (64.8) 785 (66.2) 247 (60.7)
 Female 561 (35.2) 401 (33.8) 160 (39.3)
Race
 White 1014 (63.7) 763 (64.3) 251 (61.7)
 Black 240 (15.1) 181 (15.3) 59 (14.5)
 Other 339 (21.3) 242 (20.4) 97 (23.8)
Tumor location
 Cardia 269 (16.9) 213 (18.0) 56 (13.8)
 Non-cardia 998 (62.6) 738 (62.2) 260 (63.9)
 Overlapping lesion 182 (11.4) 128 (10.8) 54 (13.3)
 Stomach, NOSb 144 (9.0) 107 (9.0) 37 (9.1)
Tumor size (mm) [median (IQR)] 55.0 (40.0, 80.0) 55.0 (40.0, 80.0) 58.0 (40.0, 80.0)
 ≤30 230 (14.4) 172 (14.5) 58 (14.3)
 31–50 466 (29.3) 343 (28.9) 123 (30.2)
 >50 897 (56.3) 671 (56.6) 226 (55.5)
Pathological subtype
 Intestinal type 317 (19.9) 219 (18.5) 98 (24.1)
 Diffuse type 167 (10.5) 106 (8.9) 61 (15.0)
 Adenocarcinoma, NOS 959 (60.2) 754 (63.6) 205 (50.4)
 Other adenocarcinoma 150 (9.4) 107 (9.0) 43 (10.6)
Grade
 Grade1/2 425 (26.7) 311 (26.2) 114 (28.0)
 Grade3/4 1168 (73.3) 875 (73.8) 293 (72.0)
T stage (AJCCc 7th)
 T1 73 (4.6) 55 (4.6) 18 (4.4)
 T2 79 (5.0) 49 (4.1) 30 (7.4)
 T3 519 (32.6) 409 (34.5) 110 (27.0)
 T4a 577 (36.2) 402 (33.9) 175 (43.0)
 T4b 345 (21.7) 271 (22.8) 74 (18.2)
N stage (AJCC 7th)
 N0 202 (12.7) 142 (12.0) 60 (14.7)
 N1 706 (44.3) 522 (44.0) 184 (45.2)
 N2 458 (28.8) 349 (29.4) 109 (26.8)
 N3 227 (14.2) 173 (14.6) 54 (13.3)
Metastatic site(s)
 Distant LN(s)d 276 (17.3) 208 (17.5) 68 (16.7)
 Viscera 1121 (70.4) 839 (70.7) 282 (69.3)
 Viscera plus distant LN(s) 118 (7.4) 96 (8.1) 22 (5.4)
 Distant metastasis, NOS 78 (4.9) 43 (3.6) 35 (8.6)
Gastrectomy
 Partial gastrectomy 808 (50.7) 612 (51.6) 196 (48.2)
 Near-total or total gastrectomy 361 (22.7) 278 (23.4) 83 (20.4)
 Gastrectomy, NOS 424 (26.6) 296 (25.0) 128 (31.4)
No. of regional LN(s) examined [median (IQR)] 13 (6, 21) 12 (6, 20) 14 (7, 22)
 ≤10 660 (41.4) 518 (43.7) 142 (34.9)
 >10 933 (58.6) 668 (56.3) 265 (65.1)
Surgery to other site(s) or node(s)
 Yes 404 (25.4) 309 (26.1) 95 (23.3)
 No 1189 (74.6) 877 (73.9) 312 (76.7)
Chemotherapy
 Yes 802 (50.3) 579 (48.8) 223 (54.8)
 No/Unknown 791 (49.7) 607 (51.2) 184 (45.2)
Radiotherapy    
 Yes 254 (15.9) 192 (16.2) 62 (15.2)
 No/Unknown 1339 (84.1) 994 (83.8) 345 (84.8)
Sequence of radiotherapy with surgery
 Pre-operative radiotherapy 69/254 (27.2) 37/192 (19.3) 32/62 (51.6)
 Post-operative radiotherapy 182/254 (71.7) 153/192 (79.7) 29/62 (46.8)
 Intraoperative or sandwich 3/254 (1.2) 2/192 (1.0) 1/62 (1.6)
  1. ainterquartile range; bnot otherwise specified; cAmerican Joint Committee on Cancer; dlymph node(s)